Samsung Bioepis, a biopharmaceutical company, and Harrow, an ophthalmic pharmaceutical firm, have jointly unveiled the results of a crucial Phase 3 clinical trial for SB11, a biosimilar referencing Lucentis (ranibizumab). The findings, presented at a recent medical conference, indicate positive outcomes for the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of vision loss among older adults.
The study, which involved a significant cohort of nAMD patients, aimed to demonstrate the equivalence of SB11 to the reference product, Lucentis, in terms of efficacy, safety, and immunogenicity. Ranibizumab works by inhibiting vascular endothelial growth factor (VEGF), a protein that plays a key role in the abnormal blood vessel growth associated with nAMD. The successful conclusion of this trial marks a significant step towards bringing SB11 to market.
Biosimilars are biological medicines that are highly similar to an already approved biological medicine (the reference product). They are developed to have the same quality, safety, and efficacy as the original product but are often available at a lower cost. The introduction of biosimilar options for complex and expensive treatments like ranibizumab is seen as a vital strategy for healthcare systems globally, including the NHS, to manage budgets and improve patient access.
The current landscape for nAMD treatment in the UK involves several anti-VEGF therapies, with Lucentis being one of the established options. The availability of a biosimilar like SB11 could intensify competition within this therapeutic area, potentially leading to more competitive pricing and broader access for patients who might otherwise face financial barriers to receiving necessary treatment. This could be particularly impactful given the increasing prevalence of age-related eye conditions in an ageing population.
While specific details regarding regulatory submissions and market availability timelines for SB11 in the UK are yet to be fully disclosed, the positive trial results are a strong indicator of its potential. The collaboration between Samsung Bioepis, known for its expertise in biosimilar development, and Harrow, with its focus on ophthalmology, positions SB11 to be a significant contender in the eye care market, offering a valuable alternative for both clinicians and patients.